Indapta Therapeutics
Business Services · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
588 Bell St Unit 1104, Seattle, Washingt...Phone Number
(917) 282-9768Website
www.indapta.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Indapta Therapeutics
Founded in 2017, Indapta is a privately-held company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The companys proprietary robust platform of naturally-occurring g-NK cells is specifically designed to create best-in-class, highly potent, more accessible, and scalable cell therapies.Explore more
Indapta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Indapta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Indapta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Indapta Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Indapta Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Indapta Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Indapta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Indapta Therapeutics launches new products
Check out if Indapta Therapeutics is spiking on competitors!
Earning: See what the market has to say on Indapta Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Indapta Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Indapta Therapeutics
Compare insights from companies similar to Indapta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Indapta Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Indapta Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Indapta Therapeutics.
Indapta Therapeutics financials insights
Gather financial insights about Indapta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$50M
2024
Other Financing Round
$22.5M
2025
Private Equity
$50.8M
Indapta Therapeutics Tech Stack
A closer look at the technologies used by Indapta Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Funding
Funding
Funding
Funding
Project
Research & Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
New Hire
Executive Move
Indapta Therapeutics News & Media
Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation cell therapies for the treatment of cancer and autoimmune diseases, announced today it has closed a $22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer (NK) cell therapy. Current investors RA Capital Management, LP, Leaps by Bayer, the impact investment arm of Bayer AG, Vertex VentIndapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced a collaboration with Sanofi to explore the combination of its allogeneic g-NK cell therapy, IDP-023, with Sanofi’s CD38-targeting monoclonal antibody, Sarclisa (isatuximab). Indapta has amended its ongoing phase 1 study of IDP-023, to add a cohort of IDP-
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Indapta Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, Indapta is a privately-held company focused on developing and bringing to market a diverse pipeline of cell therapies to treat the still unmet medical needs of patients with blood and solid-tumor cancers as well as autoimmune diseases. The companys proprietary robust platform of naturally-occurring g-NK cells is specifically design... Read More
